Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
View Patent ↗The present invention pertains to the use of BMP-2, which is overexpressed in most common cancers, as 1) a target for cancer treatment therapies and 2) a means to diagnose cancer. The therapeutic component of this invention involves administering to a patient a composition that inhibits bone morphogenetic-2 activity. Such inhibition may be accomplished by ligands or antibodies that bind to BMP-2 or BMP-2 receptors. It may also be achieved by preventing the processing of pro-BMP-2, or blocking transcription or replication of BMP-2 DNA or translation of BMP-2 mRNA. The diagnostic component of the invention involves measuring the BMP-2 level in biological samples from both a patient and a subject and comparing those levels. Elevated levels of BMP-2 in the patient compared to the non-cancerous subject indicate cancer.
1. A method for identifying a candidate agent for use in reducing vascularization in non-small cell lung tumors comprising:
(a) contacting bone morphogenetic protein-2 (BMP-2) and BMP-2 receptor IB in the presence of a test agent under conditions suitable to permit the formation of a BMP-2/BMP-2 receptor complex, wherein said BMP-2 comprises the amino acid sequence of amino acids 283-396 of SEQ ID NO: 2 and wherein said BMP-2 receptor IB comprises the amino acid sequence of amino acids 14-502 of SEQ ID NO: 14;
(b) determining the amount of the BMP-2/BMP-2 receptor complex formed in the presence of said test agent; and
(c) determining that said test agent is a candidate agent for use in reducing vascularization in non-small cell lung tumors if the amount of the BMP-2/BMP-2 receptor complex formed in the presence of said test agent is lower than the amount of the BMP-2/BMP-2 receptor complex formed in the absence of said test agent,
thereby identifying a candidate agent for use in reducing vascularization in non-small cell lung tumors.